ACADIA Pharmaceuticals (ACAD) vs IDEAYA Biosciences (IDYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 34.7% versus a loss of 8.8%. Over five years, IDYA leads with a +56.8% price change compared with +12.2% for ACAD. IDEAYA Biosciences is the larger company by market cap ($3.48 billion vs $3.39 billion), about 1.0 times the size.
ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | IDYA |
|---|---|---|
| Share price | $19.66 | $36.10 |
| Market cap | $3.39B | $3.48B |
| 1-day change | +0.05% | -0.44% |
| YTD return | -26.43% | +4.89% |
| 1-year return | -8.77% | +34.70% |
| 5-year return | +12.22% | +56.77% |
| P/E ratio (TTM) | 8.82 | — |
| Forward P/E | 22.13 | — |
| EPS (TTM) | $2.23 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | $218.71M |
| Revenue growth (YoY) | +11.87% | +3024.43% |
| Net income (latest FY) | $391.00M | $-113.70M |
| Gross margin | 91.69% | — |
| Operating margin | 9.78% | -72.84% |
| Net margin | 36.49% | -51.99% |
| 52-week high | $30.96 | $42.68 |
| 52-week low | $19.32 | $26.05 |
| Distance from 52-week high | -36.50% | -15.42% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +63.58% | +46.12% |
| Average volume | 1.84M | 785.95K |
| Shares outstanding | 172.31M | 96.49M |
| Employees | 796 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDYA has outperformed ACAD by 43.5 percentage points over the past year.
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +11.87%).
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
ACAD vs IDYA FAQ
Which is bigger, ACADIA Pharmaceuticals or IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.48B compared with $3.39B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ACAD or IDYA?
IDYA returned +34.70% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and IDEAYA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.